Site selection is one of the most underestimated and most critical success factors in radiopharmaceutical studies. Operationally, they behave differently than more traditional oncology studies. Infrastructure workflows, regulatory readiness, and timing all play a much bigger role. The ability of the investigational site as a whole is very important to the patient and drug journeys. To explore this from the clinical perspective, we are joined by Dr. Cristina Matsushita and Dr. Paolo Nunes, oncologist and senior medical director at Fortrea, with extensive hands-on experience conducting pharmaceutical clinical trials.

Host: Hector Herrero, Senior Director on Global Project Management at Fortrea

Participants: Dr. Cristina Matsushita, R2 Pharma

Dr. Paolo Nunes, Oncologist and Senior Medical Director at Fortrea